Alnylam Pharmaceuticals (ALNY) Construction in Progress (2012 - 2018)
Alnylam Pharmaceuticals' (ALNY) quarterly Construction in Progress came in at $261.0 million in Q4 2018, up 95.27% YoY from $133.6 million in Q4 2017, and up 95.27% on a QoQ basis from $133.6 million in Q4 2017.
Alnylam Pharmaceuticals (ALNY) Construction in Progress (2012 - 2018) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 7 years of Construction in Progress data on file, last reported at $261.0 million in Q4 2018.
- Quarterly Construction in Progress rose 95.27% year-over-year to $261.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $261.0 million (up 95.27% YoY) and the FY2018 annual result came in at $261.0 million, up 95.27% from the prior year.
- Construction in Progress advanced to $261.0 million in Q4 2018, from $133.6 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $261.0 million in Q4 2018 to a low of $1.3 million in Q4 2015.
- A 5-year average of $93.2 million and a median of $68.2 million in 2016 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2014 — Construction in Progress jumped 6978.57% — and 2015, when it plunged 35.17%.
- Tracing ALNY's Construction in Progress over 5 years: stood at $2.0 million in 2014, then sank by 35.17% to $1.3 million in 2015, then jumped by 5205.99% to $68.2 million in 2016, then surged by 96.01% to $133.6 million in 2017, then soared by 95.27% to $261.0 million in 2018.
- The last three Construction in Progress figures came in at $261.0 million (Q4 2018), $133.6 million (Q4 2017), and $68.2 million (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 260.98 Mn |
| Dec 31, 2017 | 133.65 Mn |
| Dec 31, 2016 | 68.18 Mn |
| Dec 31, 2015 | 1.29 Mn |
| Dec 31, 2014 | 1.98 Mn |
| Dec 31, 2013 | 28,000.00 |
| Dec 31, 2012 | 8.21 Mn |